Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2018 Sep;63(9):971-980.
doi: 10.1038/s10038-018-0478-z. Epub 2018 Jun 18.

The genotypic and phenotypic spectrum of PARS2-related infantile-onset encephalopathy

Affiliations
Clinical Trial

The genotypic and phenotypic spectrum of PARS2-related infantile-onset encephalopathy

Xiaomeng Yin et al. J Hum Genet. 2018 Sep.

Abstract

Mitochondrial aminoacyl-tRNA synthetases (mt-aaRSs) are a family of enzymes that play critical roles in protein biosynthesis. Mutations in mt-aaRSs are associated with various diseases. As a member of the mt-aaRS family, PARS2 encoding prolyl-tRNA synthetase 2 was recently shown to be associated with Alpers syndrome and certain infantile-onset neurodegenerative disorders in four patients. Here, we present two patients in a pedigree with early developmental delay, epileptic spasms, delayed myelination combined with cerebellar white matter abnormalities, and progressive cortical atrophy. Whole-exome sequencing revealed pathogenic compound heterozygous variants [c.283 G > A (p.95 V > I)] and [c.604 G > C (p.202 R > G)] in PARS2. Nearly all patients had epileptic spasms with early response to treatment, early developmental delay and/or regression followed by generalized hypotonia, postnatal microcephaly, elevated lactate levels, and progressive cerebral atrophy. Our study provides further evidence for validating the role of PARS2 in the pathology of related infantile-onset encephalopathy, contributing to the phenotypic features of this condition, and providing clinical and molecular insight for the diagnosis of this disease entity.

PubMed Disclaimer

Similar articles

Cited by

References

    1. RNA. 1997 Sep;3(9):954-60 - PubMed
    1. Eur J Hum Genet. 2000 Jan;8(1):19-23 - PubMed
    1. Annu Rev Genet. 2011;45:299-329 - PubMed
    1. Brain. 2010 Oct;133(10):2971-82 - PubMed
    1. Neurology. 2009 Feb 24;72(8):750-9 - PubMed

Publication types

Substances